Aromadendrin
Catalog No: CFN98736
Aromadendrin possesses anti-inflammatory, antioxidant, and anti-diabetic properties, it exhibits anti-inflammatory activity through the suppression of nuclear translocation of NF-κB and phosphorylation of JNK in LPS-stimulated RAW 264.7 macrophage cells. Aromadendrin treatment induces adipogenesis by increases in PPARγ2 expression, resulting in stimulation of glucose uptake and ameliorated insulin resistance, suggests that it may represent a potential therapeutic candidate for the management of type 2 DM. Aromadendrin has inhibitory activity on aldose reductase and the formation of advanced glycation end products.
Artemisinic acid
Catalog No: CFN97276
Artemisinic acid, is the immediate precursor of the semi-synthesis artemisinin, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin. Artemisinic acid has a variety of pharmacological activity, such as antimalarial, anti-tumor, antipyretic, antibacterial, allelopathy and anti-adipogenesis effects. Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression, it inhibits adipogenic differentiation of hAMSCs through reduced expression of C/EBP δ; it inhibits melanogenesis through downregulation of C/EBP α-dependent expression of HMG-CoA reductase gene.
Artepillin C
Catalog No: CFN70443
Artepillin C shows antioxidant, anti-angiogenesis, and anti-tumor activities; it also shows anti-inflammatory effects mediated, at least in part, by prostaglandin E2 and nitric oxide inhibition through NF-κB modulation. Artepillin C activates the immune system, and possesses direct antitumor activity. Artepillin C can suppress alloreactive CD4 T cell responses in vitro, so it could be used as a potential immunosuppressant, either solely or as adjunct agent in treating graft versus host disease. Artepillin C promotes adipocyte differentiation and glucose uptake in part by direct binding to PPARγ, which could be the basis of the pharmacological benefits of green propolis intake in reducing the risk of type 2 diabetes.